Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this

IMI-PainCare Initiative | PainSolve
;

Updates & Features

IMI-PainCare – Improving the Care of Patients Suffering from Acute or Chronic Pain

October 2018

Can the ambitious goals of the IMI-PainCare public-private partnership revolutionise pain research and development?

PainSolve Editorial Team

Aims of the IMI and the Pain Group collaboration

Established ten years ago, the Innovative Medicines Initiative (IMI) is a partnership between the European Commission and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).1 The IMI works to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need.1 The IMI-2 is the world’s biggest public-private partnership in life sciences, with a €3.3 billion budget for the period 2014–2020.1 Grünenthal have been involved in the ‘Patients Active in Research and Dialogues for an Improved Generation of Medicines’ (PARADIGM) project and will also join other initiatives to establish networks of specialists, including the ‘European Screening Center Unique Library of Attractive Biology’ (ESCulab), and ‘Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice’. Pain remains at the forefront of Grünenthal’s priorities, and the IMI Pain Group provides opportunities to further advance research in this area.

Like
 
Share

Share this with:

These are external links and will open in a new window